Cutaneous Lupus Erythematosus Plasma

Cutaneous Lupus Erythematosus Plasma for Autoimmune Skin Disease Research

Cutaneous Lupus Erythematosus Plasma is collected from IRB-consented donors with a clinically confirmed diagnosis of cutaneous lupus erythematosus (CLE) and processed within one day of collection to preserve cytokines, proteins, autoantibodies, and metabolites. Plasma is an acellular matrix, so it is used here for soluble-analyte work rather than cellular assays.

CLE Autoimmunity and What Plasma Reports On

CLE is an autoimmune skin disease that may occur on its own or as the cutaneous manifestation of systemic lupus erythematosus. Its biology is dominated by interferon-driven inflammation at a photosensitive skin interface:

  • Type I interferon signature. Plasmacytoid dendritic cells and nucleic-acid sensing drive a type I interferon programme that is central to CLE and is now a validated therapeutic axis in lupus
  • UV-triggered keratinocyte injury releases nuclear autoantigens, sustaining photosensitivity and the interface dermatitis pattern seen at the dermo-epidermal junction
  • Autoantibodies are measurable in plasma — ANA, and anti-Ro/SSA and anti-La/SSB in particular, which are strongly associated with subacute CLE
  • Subtype heterogeneity matters: acute CLE, subacute CLE, and chronic forms such as discoid lupus erythematosus differ in serology, scarring, and risk of progression to systemic disease
  • Soluble mediators including interferon-regulated chemokines such as CXCL10, plus complement components and cytokines, track systemic immune activation
  • Why plasma: anticoagulated collection preserves labile proteins and peptides for immunoassay, multiplex cytokine panels, proteomics, and metabolomics, and supports large aliquot counts from a single donor

Donor Stratification Available

  • CLE subtype: acute, subacute, or chronic/discoid
  • Isolated cutaneous disease versus documented concurrent systemic lupus erythematosus
  • Autoantibody status where clinically tested, including ANA and anti-Ro/SSA
  • Disease activity: active flare versus quiescent disease
  • Treatment status: treatment-naive, antimalarials, systemic immunosuppressants, or biologics
  • Age, sex assigned at birth, race/ethnicity, and smoking status
  • Matched healthy controls available

Product Features

  • Research Use Only (RUO) human plasma
  • Plasma collected from clinically confirmed cutaneous lupus erythematosus donors
  • Processed within one day of collection
  • Choice of anticoagulant available on request
  • IRB-approved protocols and electronic informed consent
  • Custom aliquot volumes available upon request

De-identified Donor Data

  • Verified cutaneous lupus erythematosus diagnosis, with subtype where documented
  • Demographic data: age, sex assigned at birth, race/ethnicity
  • Donor-reported medications, allergies, and comorbidities
  • Additional CLE-specific clinical metadata available on request

Applications

  • Type I interferon signature and interferon-regulated protein measurement
  • Autoantibody profiling, including ANA and anti-Ro/SSA and anti-La/SSB
  • Multiplex cytokine and chemokine panels
  • Complement pathway and immune-complex research
  • Proteomic and metabolomic biomarker discovery
  • Assay development and immunoassay validation for lupus analytes
  • Disease activity and flare biomarker studies
  • Comparative analysis across CLE subtypes and against systemic lupus cohorts

Other Cutaneous Lupus Erythematosus Specimen Types

Compliance and Quality Assurance

  • IRB-approved and HIPAA-compliant protocols
  • Electronic informed consent with 21 CFR Part 11-compliant e-signatures
  • Documentation support available for regulatory review

Ordering and Customization

Cutaneous lupus erythematosus plasma is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. For healthy-donor controls and the full specimen range, see our human plasma collection.

Protocols & Documentation

  • Plasma Isolation

    Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

Plasma

Frequently Asked Questions

Showing 1–12 of 31 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom Plasma cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information